BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 23897695)

  • 1. Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.
    Moreno JD; Yang PC; Bankston JR; Grandi E; Bers DM; Kass RS; Clancy CE
    Circ Res; 2013 Sep; 113(7):e50-e61. PubMed ID: 23897695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
    Fredj S; Sampson KJ; Liu H; Kass RS
    Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?
    Makielski JC; Valdivia CR
    Br J Pharmacol; 2006 May; 148(1):4-6. PubMed ID: 16520741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late sodium current associated cardiac electrophysiological and mechanical dysfunction.
    Yu S; Li G; Huang CL; Lei M; Wu L
    Pflugers Arch; 2018 Mar; 470(3):461-469. PubMed ID: 29127493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late I
    Hwang J; Kim TY; Terentyev D; Zhong M; Kabakov AY; Bronk P; Arunachalam K; Belardinelli L; Rajamani S; Kunitomo Y; Pfeiffer Z; Lu Y; Peng X; Odening KE; Qu Z; Karma A; Koren G; Choi BR
    Circ Arrhythm Electrophysiol; 2020 Aug; 13(8):e006875. PubMed ID: 32628505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A computational modelling approach combined with cellular electrophysiology data provides insights into the therapeutic benefit of targeting the late Na+ current.
    Yang PC; Song Y; Giles WR; Horvath B; Chen-Izu Y; Belardinelli L; Rajamani S; Clancy CE
    J Physiol; 2015 Mar; 593(6):1429-42. PubMed ID: 25545172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balance Between Rapid Delayed Rectifier K
    Hegyi B; Chen-Izu Y; Izu LT; Rajamani S; Belardinelli L; Bers DM; Bányász T
    Circ Arrhythm Electrophysiol; 2020 Apr; 13(4):e008130. PubMed ID: 32202931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine.
    Sicouri S; Timothy KW; Zygmunt AC; Glass A; Goodrow RJ; Belardinelli L; Antzelevitch C
    Heart Rhythm; 2007 May; 4(5):638-47. PubMed ID: 17467634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranolazine: an antianginal drug with antiarrhythmic properties.
    Tamargo J; Caballero R; Delpón E
    Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Late Sodium Current as an Innovative Antiarrhythmic Strategy.
    Bengel P; Ahmad S; Sossalla S
    Curr Heart Fail Rep; 2017 Jun; 14(3):179-186. PubMed ID: 28455610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.
    Chorin E; Hu D; Antzelevitch C; Hochstadt A; Belardinelli L; Zeltser D; Barajas-Martinez H; Rozovski U; Rosso R; Adler A; Benhorin J; Viskin S
    Circ Arrhythm Electrophysiol; 2016 Oct; 9(10):. PubMed ID: 27733495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.
    Wu L; Shryock JC; Song Y; Li Y; Antzelevitch C; Belardinelli L
    J Pharmacol Exp Ther; 2004 Aug; 310(2):599-605. PubMed ID: 15031300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization.
    Wu L; Ma J; Li H; Wang C; Grandi E; Zhang P; Luo A; Bers DM; Shryock JC; Belardinelli L
    Circulation; 2011 Apr; 123(16):1713-20. PubMed ID: 21482963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart.
    Wu L; Rajamani S; Li H; January CT; Shryock JC; Belardinelli L
    Am J Physiol Heart Circ Physiol; 2009 Sep; 297(3):H1048-57. PubMed ID: 19592609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
    Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
    J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.
    Song Y; Shryock JC; Wu L; Belardinelli L
    J Cardiovasc Pharmacol; 2004 Aug; 44(2):192-9. PubMed ID: 15243300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
    Maier LS
    J Cardiovasc Pharmacol; 2009 Oct; 54(4):279-86. PubMed ID: 19333133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability.
    Estacion M; Waxman SG; Dib-Hajj SD
    Mol Pain; 2010 Jun; 6():35. PubMed ID: 20529343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antiarrhythmic effects of ranolazine.
    Foster NJ; Haines DE
    Rev Cardiovasc Med; 2009; 10 Suppl 1():S38-45. PubMed ID: 19898287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is ranolazine an antiarrhythmic drug?
    Eckhardt LL; Teelin TC; January CT
    Am J Physiol Heart Circ Physiol; 2008 May; 294(5):H1989-91. PubMed ID: 18375723
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.